Amar Sawhney, Ph.D.
Executive Chairman of the Board
Amarpreet Sawhney, Ph.D., was elected as Executive Chairman of the Board in July 2017. Since co-founding the company in 2006, he served as President and Chief Executive Officer until 2017. Dr. Sawhney was also the CEO of Augmenix, an affiliate of Ocular Therapeutix, from 2008 until April 2014. In addition, he is a general partner of Incept, LLC, an intellectual property holding company. Previously, Dr. Sawhney founded Confluent Surgical and served as its President and CEO prior to its acquisition by Covidien plc. He also was a technology founder of Focal, Inc., a biopharmaceutical company acquired by Genzyme Corporation, and a founder of Access Closure, Inc., acquired by Cardinal Health in 2014. Dr. Sawhney’s innovations are the subject of over 100 issued and pending patents. He holds M.S. and Ph.D. degrees in chemical engineering from the University of Texas at Austin, as well as a B.Tech. in chemical engineering from the Indian Institute of Technology, Delhi India.
President, Chief Executive Officer and Director of the Board
Antony Mattessich joined Ocular as President and Chief Executive Officer in August of 2017. Mr. Mattessich brings a wealth of experience to Ocular Therapeutix as President and Chief Executive Officer, having held leadership roles for a number of global pharmaceutical companies across the US, Europe and Asia, including Novartis, Bristol Meyers Squibb and Merck & Co. Over the course of his career, Mr. Mattessich has developed expertise across multiple disciplines, including general management, global marketing, new product planning, R&D and business development. Most recently, Mr. Mattessich was the Managing Director of one of the world’s largest privately-owned pharmaceutical companies, Mundipharma. Antony holds a Master’s Degree in International Affairs from Columbia University and a Bachelor of Arts from University of California, Berkeley.
Jaswinder Chadha has served as a member of the Board of Directors since 2013. He is President, Chief Executive Officer and co-founder of Axtria, an advanced analytics company. Prior to this, Mr. Chadha served as President and CEO and was a co-founder of marketRx. He has provided sales and marketing strategies and consulting services to leading global life science companies. Mr. Chadha is a member of board of trustees of The Indus Entrepreneur (TiE) Global and is a member of the board of Panjab Digital Library (PDL). Mr. Chadha received a B.Tech. in mechanical engineering from the Indian Institute of Technology, Delhi, and an M.S. degree in industrial engineering from the University of Texas, El Paso.
Jeffrey S. Heier, M.D.
Jeffrey S. Heier, M.D. has been a member of the Board of Directors since 2015. Dr. Heier currently serves as the Co-President at Ophthalmic Consultants of Boston (OCB), one of the largest and most prestigious multi-specialty ophthalmology practices in the United States. Dr. Heier is the Co-Director of the Vitreoretinal Fellowship at OCB/Tufts Medical School in Boston, Massachusetts. Dr. Heier is on the Executive Board of the Retina Society, the Board of the American Society of Retina Specialists, and President-elect of the New England Ophthalmological Society. Dr. Heier is a member of the American Society of Retina Specialists, the Retina Society, and the Macula Society. Dr. Heier is one of the leading retinal clinical researchers in the country for new treatments in exudative and non-exudative macular degeneration, diabetic macular edema, venous occlusive disease, vitreoretinal surgical techniques and instrumentation and diagnostic imaging of the retina. He serves on the scientific advisory board or as Clinical Design Consultant to over thirty biotechnical or pharmaceutical companies. Dr. Heier received his medical degrees from Boston University and completed his ophthalmology residency at Fitzsimons Army Medical Center. He also completed a vitreoretinal fellowship at OCB/Tufts University School of Medicine.
Richard Lindstrom, M.D.
Richard Lindstrom, M.D., has served on the Board of Directors since 2012. Dr. Lindstrom is a Founder, Director and Attending Surgeon at Minnesota Eye Consultants, P.A., a provider of eye care services. A Board-certified ophthalmologist and internationally recognized leader in corneal, cataract, refractive and laser surgery, Dr. Lindstrom has developed a number of solutions, intraocular lenses and instruments that are used in clinical practices globally. He is Adjunct Clinical Professor Emeritus: University of Minnesota, Department of Ophthalmology. He is the Associate Director of the Minnesota Lions Eye Bank, Board Member: University of Minnesota Foundation, Visiting Professor, UC Irvine: Gavin Herbert Eye Institute. He also is past President of the American Society of Cataract and Refractive Surgeons and the International Society of Refractive Surgery. Dr. Lindstrom holds a B.A. degree in pre-medical studies, a B.S. degree in medicine and an M.D. degree from the University of Minnesota.
W. James O’Shea
W. James O’Shea has been a member of the Board of Directors since 2015. For nearly a decade, Mr. O’Shea held leadership positions at Sepracor, Inc. He served as President and Chief Operating Officer, where he was responsible for building the organization’s commercial infrastructure and led the successful launch and commercialization of Xopenex® and Lunesta®. He also served as Vice Chairman. Prior to Sepracor, Mr. O’Shea was Senior Vice President of Sales and Marketing and Medical Affairs for Zeneca Pharmaceuticals, a business unit of Astra Zeneca Plc. While at Zeneca, he also held management positions of increasing responsibility in international sales and marketing in the US and UK. Mr. O’Shea is a past Chairman of the National Pharmaceutical Council and serves on the board of directors of BTG Plc, and Trevi Therapeutics, and also is Chairman of Cardiome. Mr. O’Shea is a graduate of Liverpool Lord Byron University. He also received an honors degree in applied physics from the Institute of Physics in London.
Bruce Peacock has been on the Board of Directors since 2014. He currently serves as a Venture Partner at SV Life Sciences and was previously Chief Financial Officer and Business Officer of Ophthotech Corporation, an ophthalmology-focused biopharmaceutical company. During his career, he has held numerous senior leadership roles, including President and Chief Executive Officer of Alba Therapeutics, Adolor Corporation and Orthovita, Inc. He has held positions at Cephalon, Inc., including Executive Vice President, Chief Operating Officer and Chief Financial Officer. Prior to this, he was Chief Financial Officer at Centocor. Mr. Peacock serves as a member of the Board of Directors at Alba Therapeutics, where he is Co-Chairman, Windtree Therapeutics, Invisible Sentinel, Dicerna Pharmaceuticals, PanOptica, Inc. and CARMA Therapeutics. Mr. Peacock holds a bachelor’s degree in business administration from Villanova University and is a certified CPA.
Charles Warden has been on the Board of Directors since 2008. He is Managing Director at Versant Ventures, a leading venture capital firm specializing in biopharmaceutical and medical device companies. Previously, Mr. Warden was General Partner at Schroder Ventures Life Sciences, now part of SV Life Sciences. Prior to this, he worked with Boston Capital Ventures and with Monitor Company, a strategy consulting firm. Mr. Warden serves on a number of boards of privately held life sciences companies and is actively involved with several incubators, including ForSight Labs, The Foundry and The Innovation Factory. Mr. Warden received a B.A. degree in economics and classics from Beloit College and an M.B.A. degree from Harvard University.